L. Dépistage, Prévention des Handicaps de l'Enfant) The PHRC and CNAM did not 348 participate in the study or its interpretation. AFDPHE was involved in the conduction of the 349 study and its president

C. Dr and . Bouvattier, Kremlin-Bicêtre; Prof. Régis Coutant, Anger; Dr Luc Desfrère, Colombes; Prof, p.356

M. Raux-demay, . Paris, and . Prof, Maité Tauber, Toulouse 358 Members of regional screening associations who organized and conducted the study, p.359

M. Comte and . Gaulard, Dr Schirrer

P. Saint-dizier, M. Sarda-;-limousin, and . Chebroux, Dr Constanty

M. Rue and . Fauvel, Ms Mirallié, Prof. Barriere; Nord-Pas-de-Calais, Prof. Olives; Nantes

M. Grenoble, M. Gachet, and . Picard, Prof. Debillon; Rhone-Alpes Lyon

. Prof, Dr Tardy, Lyon; Dr Bellane-Chantelot, Paris-Pitié Salpétrière; Prof. Clauser, Paris-Cochin. 370 Physicians who participated in the evaluation and management of screened newborns 371

D. Gounot and . Prof, Huet, Dijon; Dr Loeuille, Dunkerque; Dr Dulucq, p.378

Y. Prof, . Brauner, and . Le-kremlin-bicêtre, Le-Mans; Dr Maxaud, Le-Mans

R. Idres, Saint-Brieux; Dr Raynaud-Ravni, Saint-Etienne; Dr Chouraki, Saint-Quentin, p.389

. Stdenis-laréunion, Dr Petrus, Tarbes; Dr Feldmann, p.390

P. White and P. Speiser, Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency, Endocrine Reviews, vol.21, issue.3
DOI : 10.1210/er.21.3.245

D. Merke and S. Bornstein, Congenital adrenal hyperplasia. Lancet, pp.2125-398, 2005.

P. Speiser, R. Azziz, and L. Baskin, Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.9, pp.4133-4160, 2010.
DOI : 10.1210/jc.2009-2631

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936060

T. Johannsen, D. Mallet, and H. Dige-petersen, Delayed diagnosis of congenital adrenal hyperplasia 403 with salt wasting due to type II 3beta-hydroxysteroid dehydrogenase deficiency, J Clin Endocrinol Metab

S. Pang, M. Wallace, and L. Hofman, Worldwide experience in newborn screening for classical 406 congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics, Jun, vol.81, issue.6, pp.866-874, 1988.

J. Wilson, The evaluation of the worth of early disease detection, J R Coll Gen Pract. Nov, vol.16, 1968.

S. Grosse, V. Vliet, and G. , How many deaths can be prevented by newborn screening for congenital 410 adrenal hyperplasia?, Horm Res, vol.67, issue.6, pp.284-291, 2007.

J. Loeber, Neonatal screening in Europe; the situation in 2004, Journal of Inherited Metabolic Disease, vol.2, issue.4, pp.430-438, 2007.
DOI : 10.1007/s10545-007-0644-5

N. Janzen, M. Peter, and S. Sander, Newborn Screening for Congenital Adrenal Hyperplasia: Additional Steroid Profile using Liquid Chromatography-Tandem Mass Spectrometry, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.7, pp.2581-2589, 2007.
DOI : 10.1210/jc.2006-2890

M. Cartigny-maciejewski, N. Guilley, and S. Vanderbecken, Neonatal screening of congenital adrenal 419 hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980-1996. Arch Pediatr, Feb, vol.4206, issue.2, pp.151-158, 1999.

J. Dhondt and J. Farriaux, The wonderful history of neonatal screening, Ann Biol Clin, vol.58, issue.3, pp.267-276, 2000.

Y. Morel and W. Miller, Clinical and molecular genetics of congenital adrenal hyperplasia due to, pp.21-424

V. Tardy, R. Menassa, and V. Sulmont, Phenotype-Genotype Correlations of 13 Rare CYP21A2 Mutations Detected in 46 Patients Affected with 21-Hydroxylase Deficiency and in One Carrier, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.3, pp.1288-1300, 2010.
DOI : 10.1210/jc.2009-1202

P. Van-dommelen, J. Van-wouwe, J. Breuning-boers, S. Van-buuren, and P. Verkerk, Reference chart for relative weight change to detect hypernatraemic dehydration, Archives of Disease in Childhood, vol.92, issue.6, pp.490-494, 2007.
DOI : 10.1136/adc.2006.104331

A. Nordenstrom, A. Wedell, L. Hagenfeldt, C. Marcus, and A. Larsson, Neonatal screening for congenital 432

T. Wong, C. Shackleton, T. Covey, and G. Ellis, Identification of the steroids in neonatal plasma that 435 interfere with 17 alpha-hydroxyprogesterone radioimmunoassays, Clin Chem. Sep, vol.38, issue.9, pp.1830-1837, 1992.

S. Saedi, H. Dean, W. Dent, and C. Cronin, Reference ranges for serum cortisol and 17-hydroxyprogesterone levels in preterm infants, The Journal of Pediatrics, vol.126, issue.6, pp.985-987, 1995.
DOI : 10.1016/S0022-3476(95)70229-6

C. Minutti, J. Lacey, and M. Magera, Steroid profiling by tandem mass spectrometry improves the 439

J. Kovacs, F. Votava, and G. Heinze, Lessons from 30 years of clinical diagnosis and treatment of 442 congenital adrenal hyperplasia in five middle European countries, J Clin Endocrinol Metab, vol.86, issue.7, pp.2958-2964, 2001.

B. Yoo and S. Grosse, The cost effectiveness of screening newborns for congenital adrenal hyperplasia. 445 Public Health Genomics, pp.67-72, 2009.

B. Therrell, S. Berenbaum, and V. Manter-kapanke, Results of screening 1.9 million Texas 447 newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics, pp.583-590, 1998.

M. Steigert, E. Schoenle, A. Biason-lauber, and T. Torresani, High Reliability of Neonatal Screening for Congenital Adrenal Hyperplasia in Switzerland, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.9, pp.4106-4110, 2002.
DOI : 10.1210/jc.2002-012093

H. Van-der-kamp, K. Noordam, B. Elvers, M. Van-baarle, B. Otten et al., Newborn Screening for Congenital Adrenal Hyperplasia inthe Netherlands, PEDIATRICS, vol.108, issue.6, pp.1320-1324, 2001.
DOI : 10.1542/peds.108.6.1320

*. Delfia®, dissociation-enhanced lanthanide fluorescence immunoassay; RIA, radioimmunoassay; missing data: 510 Laboratory methods